Slower Procedure Growth Change The Bull Case For Intuitive Surgical Stock?
- Intuitive Surgical reported Q3 2026 revenue of US$3,048.7 million compared with US$2,505.1 million a year earlier, while net income declined to US$522.8 million from US$704.4 million, and diluted EPS from continuing operations moved to US$1.49 from US$1.95.
- The business is accepting lower instrument and accessory revenue per procedure and absorbing a US$450 million antitrust settlement charge as it focuses on da Vinci procedure volume in high volume benign surgeries. This is occurring even as U.S. procedure growth slowed to 10% and management narrowed the full year outlook to a range of 14% to 15%.
- We will now test how Intuitive Surgical's slower da Vinci procedure growth and margin pressure reshape the investment narrative investors have relied on.
Intuitive Surgical Investment Narrative Recap
To own Intuitive Surgical, you need to believe that growing global use of robotic surgery and a larger installed base can support recurring instruments, accessories, and service income over time. The latest quarter complicates that picture. U.S. da Vinci procedure growth slowed to 10%, margins were under pressure, and the stock sold off, so near term sentiment is more fragile.
The key short term catalyst is still procedure growth on da Vinci and Ion systems. Management is accepting lower instrument revenue per procedure and absorbing a US$450 million settlement charge while pushing into high volume benign surgeries. The biggest risk right now is that slower U.S. growth and pricing pressure persist long enough to weigh on recurring revenue and profitability.
The most relevant disclosure for this setup is the Q3 2026 earnings report. Intuitive Surgical reported quarterly revenue of US$3,048.7 million compared with US$2,505.1 million a year earlier, while net income moved to US$522.8 million from US$704.4 million and diluted EPS from continuing operations shifted to US$1.49 from US$1.95.
Those figures sit alongside nine month revenue of US$8,711.8 million versus US$7,198.5 million and net income of US$2,162.4 million compared with US$2,061.2 million, with diluted EPS from continuing operations at US$6.07 versus US$5.67. For you, the tension is clear. Installed base and recurring exposure remain important operational strengths, while the latest quarter underlines that pricing, policy, and competitive pressure can quickly affect earnings and the near term catalyst path.
Intuitive Surgical's current earnings are US$3.1b, with analysts forecasting earnings of US$4.8b by 2029. This is an increase of about US$1.7b, while analysts are also projecting revenue growth of 11.9% per year that would take total revenue to US$15.5b in 2029.
Uncover how Intuitive Surgical's fair value indicates a 5% potential upside to its current price, which could narrow quickly if sentiment improves further.
Exploring Other Perspectives
One bullish twist you might consider is how optimistic analysts were about Intuitive Surgical cutting cost per procedure. Before this Q3 report, the highest forecasts were built around revenue reaching US$17.4b and earnings of US$5.1b by 2029. Those upbeat expectations did not factor in slower U.S. procedures or the US$450m settlement, so views may shift from here.
Explore 8 other Intuitive Surgical fair value estimates, including one that suggests as much as 39% upside from the current price.
Reach Your Own Conclusion
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for Intuitive Surgical. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Intuitive Surgical's overall financial health at a glance.
Looking for more investment ideas beyond Intuitive Surgical?
If this Intuitive Surgical update has sharpened your view on procedure driven healthcare, you can use that same lens to evaluate other businesses with different strengths in cash flow, balance sheet resilience, or income potential.
- For investors who want quality at a sensible entry point, start by scanning a focused group of 27 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect them.
- If balance sheet strength is your anchor, filter for companies that prioritize financial resilience and liquidity using the list of solid balance sheet and fundamentals (25 results) to see which ones meet your risk tolerance.
- When you want ideas that are off most radars, widen your research with a curated pool of 21 high quality undiscovered gems that pair fundamental strength with lower mainstream attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com